Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer.

Paola Gazzaniga, Italo Nofroni, Orietta Gandini, Ida Silvestri, Luigi Frati, Anna Maria Aglianò, Angela Gradilone

Research output: Contribution to journalArticlepeer-review


Tenascin C has been recently suggested as a tumor marker, however, its levels in serum has been evaluated only in patients with head and neck cancer and melanoma. In this study, we investigated Tenascin C expression in blood samples from colorectal and bladder cancer patients, compared to that of epidermal growth factor receptor (EGFR), a known circulating tumor marker in these cancer types. RT-PCR specific for Tenascin C and EGFR was performed on RNAs extracted from blood samples of 60 patients affected by colon or bladder cancer. We then investigated the statistical association between Tenascin C, EGFR expression and disease-free survival using the Kaplan-Meier method. Furthermore, in order to select which variable between EGFR and Tenascin C was the most predictive for recurrence, a Cox model for proportional risk was applied. Among all patients analysed, a significantly higher disease-free time was found in the group negative for both EGFR and Tenascin C expression; EGFR expression was significantly correlated to disease progression in stages III and IV, whereas in all patients with stage I and II disease Tenascin C correlated better with prognosis. Negative expression of both EGFR and Tenascin C identifies a group of patients with poor tendency to disease recurrence and longer relapse-free time. While Tenascin C expression seems to influence prognosis in patients with low-stage disease, EGFR appears a marker of worse prognosis in patients with high-staged tumors.

Original languageEnglish
Pages (from-to)1199-1202
Number of pages4
JournalOncology Reports
Issue number5
Publication statusPublished - Nov 2005

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer.'. Together they form a unique fingerprint.

Cite this